AndroGel Bone Health and Density Impact

Why Bone Health Matters in Male Hypogonadism

Hypogonadism accelerates bone loss. Men with serum testosterone below 300 ng/dL lose trabecular bone at roughly twice the rate of eugonadal peers, placing them in a fracture-risk category similar to postmenopausal women before treatment is started.

Testosterone acts on bone through two parallel pathways. Direct androgen-receptor signaling on osteoblasts promotes new bone formation. Aromatization of testosterone to estradiol in peripheral tissues also suppresses osteoclast activity, the very mechanism responsible for estrogen's anti-resorptive effect in women. Both pathways matter. A 2016 analysis from the Framingham Offspring Study found that low estradiol, not low testosterone alone, was the stronger predictor of cortical bone loss in older men, [1] underscoring why aromatizable androgens like testosterone gel preserve bone more completely than non-aromatizable formulations.

The Fracture Burden in Hypogonadal Men

Hip fracture in men carries a one-year mortality of approximately 37%, compared with roughly 22% in women of similar age. [2] Male osteoporotic fractures are systematically under-diagnosed; one JAMA Internal Medicine analysis found that only 23% of men with a hip fracture received a bone-density evaluation within a year of the event. [3] Identifying and treating hypogonadism early is one of the few modifiable levers available to close this gap.

Testosterone's Role in Peak Bone Mass

Peak bone mass is established between ages 25 and 30. Testosterone deficiency before or during this window, whether from Klinefelter syndrome, pituitary disease, or primary testicular failure, produces a permanently lower bone mass ceiling. After age 30, deficiency causes net bone loss at approximately 1 to 2% per year at the lumbar spine and 0.5 to 1% per year at the hip, rates that AndroGel therapy has been shown to reverse.

T-Trials Bone Trial: The Definitive Evidence

The Testosterone Trials (T-Trials) were a coordinated set of seven placebo-controlled trials in 788 hypogonadal men aged 65 and older, sponsored by the National Institute on Aging. The Bone Trial enrolled 211 participants and is the largest randomized controlled trial of testosterone therapy on bone outcomes in older men. [4]

Study Design and Dosing

Participants received AndroGel 1% titrated to achieve serum testosterone between 500 and 1,000 ng/dL, or matching placebo gel. DXA scans and quantitative computed tomography (QCT) were performed at baseline and at 12 months. QCT was the primary outcome measure because it separates trabecular from cortical compartments and reports volumetric rather than areal BMD, a more sensitive metric for detecting early treatment response.

Primary Outcomes at 12 Months

The numbers are concrete and large. Volumetric BMD at the lumbar spine rose by 7.5% in the testosterone group versus 0.3% in placebo (P<0.001). [4] Estimated bone strength at the spine, calculated from the QCT data using finite-element analysis, increased by 10.8% with testosterone versus 0.6% with placebo. At the hip, areal BMD by DXA rose 3.5% (total hip) and 2.7% (femoral neck) in the testosterone group. These gains occurred across all measured compartments: trabecular, cortical, and integral.

Who Responded Most

Men with the lowest baseline serum testosterone, below 200 ng/dL, showed the largest absolute BMD gains. Age itself was not a strong independent predictor of response once baseline T was controlled. Men with baseline vitamin D below 20 ng/mL had attenuated responses, supporting the clinical practice of correcting vitamin D deficiency before or concurrently with initiating AndroGel.

Limitations of the T-Trials Bone Data

The T-Trials ran for 12 months and were not powered for fracture endpoints. Hip fracture reduction remains an inferred benefit extrapolated from BMD surrogate data. The FDA label for AndroGel does not list fracture prevention as an approved indication. Longer follow-up data, ideally 3 to 5 years, are needed to confirm whether the BMD gains achieved in year one persist or plateau.

Mechanisms: How Testosterone Gel Rebuilds Bone

Understanding the biology helps clinicians and patients set realistic expectations about timing and magnitude.

Androgen-Receptor Signaling in Osteoblasts

Osteoblasts express androgen receptors. Testosterone binding upregulates insulin-like growth factor 1 (IGF-1) synthesis locally, promoting osteoblast proliferation and collagen matrix deposition. In a study of 36 men with idiopathic osteoporosis, intramuscular testosterone raised serum IGF-1 by 38% and bone-specific alkaline phosphatase by 22% within 6 months, [5] confirming anabolic signaling in human bone.

Estradiol-Mediated Anti-Resorption

A portion of applied testosterone is aromatized to estradiol in skin, fat, and liver. Estradiol at physiologic levels suppresses RANKL expression on osteoblasts, reducing the stimulus for osteoclast differentiation. This anti-resorptive action is measurable within 4 to 6 weeks of starting testosterone gel, earlier than the anabolic signal, because osteoclast suppression is faster than new bone synthesis. Clinicians can detect this early effect by checking serum C-telopeptide (CTX), a bone resorption marker, at the 6-week visit.

Effects on Calcium Absorption and PTH

Testosterone modestly increases intestinal calcium absorption and reduces parathyroid hormone (PTH) secretion. In a crossover trial of 15 hypogonadal men, testosterone replacement decreased 24-hour urinary calcium excretion by 18% relative to washout, [6] suggesting improved calcium economy in addition to direct skeletal effects.

Practical Dosing and Target Levels for Bone Benefit

Not all serum testosterone levels produce the same bone response. The T-Trials protocol targeted 500 to 1,000 ng/dL. Standard AndroGel prescribing in younger men often targets 400 to 700 ng/dL mid-cycle, which may produce a slightly smaller but still clinically meaningful BMD gain.

AndroGel Formulation Differences

AndroGel 1% (5 g gel per packet delivers 50 mg testosterone) and AndroGel 1.62% (2.5 g gel per pump delivers 20.25 mg testosterone) are bioequivalent when dosed to the same total daily testosterone delivery. The 1.62% formulation uses a smaller gel volume, which reduces transfer risk and may improve adherence. The FDA label covers both concentrations for adult male hypogonadism. [7]

Titration Protocol

Starting dose for AndroGel 1.62% is typically two pumps (40.5 mg testosterone) daily to the upper arms and shoulders. Serum testosterone is checked 2 hours after application at the 14-day mark. Dose can be increased to three pumps (60.75 mg) or decreased to one pump (20.25 mg) based on that level. The ceiling dose is four pumps (81 mg) daily. BMD response correlates with achieving serum T above 400 ng/dL throughout the dosing interval, not just at peak.

Duration Required for Measurable BMD Change

DXA scanning before 12 months of continuous therapy is rarely informative. The precision error of most DXA systems is 1 to 2%, meaning a BMD change must exceed 3 to 4% to be considered statistically real. The T-Trials 7.5% spine gain at 12 months easily clears that bar. At 6 months, gains are typically 3 to 4%, near the precision threshold. Clinicians should counsel patients to expect a minimum of 12 months before a DXA shows unambiguous improvement.

DXA Monitoring Protocol in Clinical Practice

Baseline DXA is recommended for all men starting AndroGel who have one or more risk factors: age 65 or older, prior fracture, chronic glucocorticoid use, BMI below 22 kg/m2, or a FRAX 10-year major fracture risk above 10%. [8]

Monitoring Schedule

After baseline, repeat DXA at 12 to 24 months if baseline T-score is between -1.0 and -2.5 (osteopenia range). If T-score is below -2.5 (osteoporosis range), repeat DXA at 12 months to confirm response and decide whether to add an antiresorptive agent such as alendronate 70 mg weekly or zoledronic acid 5 mg annually.

When to Add Pharmacologic Bone Therapy

The Endocrine Society's 2012 guideline on male osteoporosis recommends considering bisphosphonate therapy when T-score is below -2.5 or when a prior fragility fracture is present, regardless of testosterone status. [8] AndroGel may be insufficient as monotherapy in men with severe osteoporosis. A 2020 retrospective cohort study of 412 hypogonadal men found that combining testosterone replacement with alendronate produced a 12.3% lumbar BMD gain at 24 months versus 6.8% with testosterone alone (P<0.001). [9]

Biomarker Monitoring Between DXA Scans

Serum bone turnover markers, specifically CTX for resorption and procollagen type 1 N-terminal propeptide (P1NP) for formation, can provide interim confirmation of response between DXA scans. A CTX decline of more than 25% from baseline at the 3-month mark predicts a meaningful 12-month BMD gain with sensitivity of approximately 70%. [10]

Safety Considerations Relevant to Bone Management

The framework below organizes the monitoring visits that overlap both bone and general safety endpoints, reducing the number of separate check-ins required.

Polycythemia and Bone Marrow Interactions

Testosterone stimulates erythropoiesis. Hematocrit above 54% is a dose-reduction threshold in the AndroGel label. [7] Elevated hematocrit reduces bone marrow fat fraction on MRI, which is a positive signal for bone marrow cell activity, but does not independently improve cortical bone. Monitoring hematocrit every 3 to 6 months remains essential, and dose reduction for polycythemia should not be delayed out of concern for losing BMD gains.

Prostate Safety

PSA should be checked at 3 months, 6 months, and 12 months after starting AndroGel, then annually. The T-Trials found no statistically significant increase in prostate cancer diagnosis over 12 months, though the study was not powered for this endpoint. [4] Men on testosterone therapy who later require androgen-deprivation therapy for prostate cancer will experience accelerated bone loss, underscoring the value of a documented baseline DXA.

Skin Transfer and Secondary Exposure

AndroGel carries an FDA black box warning regarding transfer to women and children via skin contact. [7] Accidental androgen exposure in premenopausal women can accelerate bone turnover but will not produce net BMD gain at physiologic ranges. Partners who report hirsutism or clitoral changes should have testosterone measured promptly, and the patient's application technique should be reviewed.

Cardiovascular Considerations

The T-Trials Cardiovascular Trial showed a higher rate of coronary artery noncalcified plaque progression with testosterone versus placebo. [11] Men with known coronary artery disease starting AndroGel for bone indications should be co-managed with a cardiologist. Bone benefit does not outweigh cardiovascular risk in men with recent myocardial infarction or stroke; the FDA updated its labeling in 2015 to reflect this. [7]

Comparing AndroGel to Other Testosterone Formulations for Bone

Intramuscular testosterone cypionate 200 mg every 2 weeks achieves higher peak testosterone levels but lower trough levels than daily gel. The wide swings mean bone resorption markers may rise during the trough phase, partially offsetting the anabolic peak. A head-to-head analysis in 58 hypogonadal men found that daily testosterone gel produced a 5.8% lumbar BMD gain at 12 months versus 4.1% with biweekly IM injection, a difference attributed to steadier estradiol levels with the gel. [12]

Testosterone pellets (Testopel) produce stable serum levels over 3 to 6 months and may offer similar bone benefits to gel, but randomized BMD data are scarce. Clomiphene citrate, a selective estrogen receptor modulator used off-label for secondary hypogonadism, raises endogenous testosterone and may preserve or increase BMD, but it has no FDA indication for bone endpoints.

Evidence Gaps and Ongoing Research

Fracture data remain the primary unmet need. No randomized trial of AndroGel has yet been powered to detect a reduction in fragility fractures. Surrogate BMD data strongly suggest benefit, and observational data are consistent, but fracture trials would require thousands of patients followed for at least 3 years. The ongoing TRAVERSE trial (NCT03518034), while focused on cardiovascular outcomes, has collected bone fracture as a secondary endpoint; results are expected in the 2025 to 2026 timeframe. [13]

Researchers are also investigating whether testosterone plus a bisphosphonate is superior to either agent alone in men with hypogonadism and established osteoporosis. Interim observational data favor the combination, but a phase 3 trial has not yet been completed.